Study of the CD40 Agonistic Monoclonal Antibody APX005M
NCT02482168
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
NSCLC
Melanoma
Urothelial Carcinoma
MSI-H
Head and Neck Cancer
Interventions
DRUG:
APX005M
Sponsor
Apexigen America, Inc.